Stryker (SYK) Stock Forecast & Price Target

Stryker demonstrated robust financial performance with a notable operating margin improvement to 30.2%, exceeding consensus expectations and reflecting operational efficiency and strong demand for its innovative products. Organic sales growth reached 11.0% in 4Q25, driven by increased procedure volumes, particularly in robotic assisted knee surgeries and new Mako installation momentum, alongside significant growth in key segments such as Peripheral Vascular and Neurotechnology. The company's diverse product portfolio, coupled with broad-based strength across various business lines, positions Stryker favorably in the competitive landscape of medical equipment and devices, particularly as a leader in orthopedic implants and operating room equipment.

Stryker faces multiple challenges that contribute to a negative outlook on its stock, including disruptions from recent acquisitions and a deceleration in Mako utilization as competitors enter the market. Projections indicate organic revenue growth may slow to 8% or less, exacerbated by unsuccessful new product launches and revenue dis-synergies from acquisitions; this could result in below-consensus earnings and diminished gross margins. Additionally, factors such as slower orthopedic market growth, reduced hospital capital spending, and potential tariff headwinds further complicate Stryker's financial health, particularly as demonstrated by a decline in gross margins and the stock's underperformance relative to peers.